What people are saying - Write a review
We haven't found any reviews in the usual places.
Corporate finance for biotech
a private vs public perspective Montgomery Securities
2 other sections not shown
academic activities agencies Agracetus Agreement agricultural Amgen approval areas biogenic ice nuclei biotech patents biotechnology companies biotechnology industry Biotechnology patent biotechnology products Cetus chemical collaboration commercial competitive Court disclosure drug environment environmental evaluate example Federal filed financial modeling firms funding future Genentech genetically engineered organisms Hybritech ice nuclei Immunex important infringement initial public offerings Institute intellectual property Interleukin invention investors involved issues joint ventures license major Minnesota molecular biology Monoclonal Antibodies nations nology patent application patent attorney patent laws patent litigation patent prosecution patent strategies pesticide potential programs proprietary proteins proteins and peptides public offerings recombinant DNA regulations regulatory result safety and health scientific scientists small biotech company Sponsor start-ups strategic alliances success tissue plasminogen activator U.S. Patent U.S. Patent Office University valuation venture capital